Hyoscine butylbromide (Buscopan) injection: risk of serious adverse effects in patients with underlying cardiac disease

Prescribing information has been updated to help to minimise the risk of serious adverse reactions in patients with cardiac disease.

Yellow Card reporting added to second clinical software system

Healthcare professionals who use Vision can now report suspected adverse reactions to MHRA directly through their clinical software.

Letters sent to healthcare professionals in January 2017

A summary of letters sent to relevant healthcare professionals in January 2017.

Posted on the UK MHRA website on 20 February 2017